CN112426491A - 一种治疗恶性黑色素瘤的中药组合物 - Google Patents
一种治疗恶性黑色素瘤的中药组合物 Download PDFInfo
- Publication number
- CN112426491A CN112426491A CN202010821414.6A CN202010821414A CN112426491A CN 112426491 A CN112426491 A CN 112426491A CN 202010821414 A CN202010821414 A CN 202010821414A CN 112426491 A CN112426491 A CN 112426491A
- Authority
- CN
- China
- Prior art keywords
- parts
- malignant melanoma
- traditional chinese
- chinese medicine
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 48
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims description 12
- 235000005340 Asparagus officinalis Nutrition 0.000 claims abstract description 8
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 7
- 244000068988 Glycine max Species 0.000 claims abstract description 7
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 7
- 239000003610 charcoal Substances 0.000 claims abstract description 7
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 7
- 241000218989 Trichosanthes Species 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 241000221079 Euphorbia <genus> Species 0.000 claims abstract description 5
- 235000008694 Humulus lupulus Nutrition 0.000 claims abstract description 5
- 241000029486 Stephania sinica Species 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 244000003416 Asparagus officinalis Species 0.000 claims abstract 3
- 239000007788 liquid Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 10
- 230000006907 apoptotic process Effects 0.000 abstract description 6
- 230000004069 differentiation Effects 0.000 abstract description 5
- 206010027476 Metastases Diseases 0.000 abstract description 4
- 230000009401 metastasis Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 208000006332 Choriocarcinoma Diseases 0.000 abstract description 2
- 230000036737 immune function Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 241000234427 Asparagus Species 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000000225 Euphorbia hirta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001078983 Tetradium ruticarpum Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗恶性黑色素瘤的中药，是由下列重量份的原料药组成：吴茱萸2～4重量份；金不换、啤酒花4～8重量份；天花粉、龙牙草10～20重量份；黑大豆、飞扬草、将军炭15～30重量份；芦笋30～60重量份。本发明可以增强机体免疫功能，杀死恶性黑色素瘤细胞、诱导恶性黑色素瘤细胞分化和凋亡、防止恶性黑色素瘤细胞转移，减轻患者痛苦、提高病人生存质量，提高了恶性黑色素瘤患者的治愈率，具有治疗效果显著、无毒副作用等特点。本发明还可以有效治疗绒膜癌。
Description
技术领域
本发明涉及中药的制备领域，特别是涉及一种治疗恶性黑色素瘤的中药组合物。
背景技术
恶性黑色素瘤，是黑色素细胞来源的一种高度恶性的肿瘤，多发生于皮肤，也可见于黏膜和内脏，约占全部肿瘤的3%。近年来，恶性黑色素瘤的发生率和死亡率逐年升高，与其他实体瘤相比，其致死年龄更低。
传统治疗方法有种种缺陷，恶性黑色素瘤除早期手术切除外，缺乏特效治疗，预后差。手术治疗能将肿瘤切除，但是，手术风险高，手术对人体创伤大，使患者免疫力降低，对疾病抵抗力下降，手术为局部治疗手段，只适用于早期且身体状况能够耐受的患者；手术切除不能除根，会直接导致恶性黑色素瘤细胞扩散。
化疗的疗效欠佳。适合于已有转移的晚期患者。部分患者应用化疗后，可缓解症状，延长存活时间。化疗药物几乎都是细胞毒性药物，在杀死肿瘤细胞的同时，对人体的正常细胞有一定的毒副作用，尤其是对分裂、增殖、比较快的细胞如骨髓造血细胞、胃肠道粘膜上皮细胞等。化疗会缩短患者生存时间且部分肿瘤对药物不敏感，化疗不可能彻底杀死体内所有恶性黑色素瘤细胞，在一定的时间内恶性黑色素瘤细胞还会复发或转移。
恶性黑色素瘤对放射治疗不敏感，仅用于特殊情况下的辅助治疗，如不能耐受手术、手术切除不尽但又无法再次手术、或脑和骨转移后的姑息治疗，以及小型或中型脉络膜恶性黑色素瘤的治疗。放射治疗常作为一种辅助治疗或姑息治疗手段。放射治疗在破坏肿瘤的同时，正常组织细胞也会受到一定的损害，超过这一限制剂量就会对组织产生不可逆损害，而且，放射治疗还可能降低机体的免疫力。放射的剂量是经过理论计算来完成，难以与实际相符合，只有小于 2cm 的肿瘤才能一次性完全破坏。
发明内容
本发明的目的在于改进已有技术的不足而提供一种治疗恶性黑色素瘤的中药组合物，使其可以有效的抵抗恶性黑色素瘤细胞、防止恶性黑色素瘤细胞转移，提高了恶性黑色素瘤患者的治愈率，具有治疗效果显著、无毒副作用等特点。
本发明提供了一种治疗恶性黑色素瘤的中药组合物，该中药组合物包括：吴茱萸2～4重量份；金不换、啤酒花4～8重量份；天花粉、龙牙草10～20重量份；黑大豆、飞扬草、将军炭15～30重量份；芦笋30～60重量份。
在一个优选的实施方案中，所述治疗恶性黑色素瘤的中药组合物由下列重量份的原料药组成：吴茱萸4重量份；金不换、啤酒花8重量份；天花粉、龙牙草20重量份；黑大豆、飞扬草、将军炭30重量份；芦笋60重量份。
其中，黑大豆：甘；平。归脾；肾；心经活血利水；祛风解毒；健脾益肾。黑大豆明显降低黑色素瘤克隆形成能力和体内成瘤能力，明显改变黑色素瘤细胞形态，诱导其分化。
飞扬草：微苦、微酸，凉。清热解毒，利湿止痒。飞扬草能特异性地杀死黑色素瘤。
吴茱萸：辛、苦，热；有小毒。归肝、脾、胃、肾经。散寒止痛，降逆止呕，助阳止泻。吴茱萸能诱导A375-S2恶性黑色素瘤细胞凋亡。
龙牙草：味苦、涩，性平。归肺；肝；脾经，收敛止血，止痢，杀虫。龙牙草有稳定而显著的抗肿瘤作用，经体外试验对恶性黑色素瘤细胞有强烈的抑制作用，抑制率在70％－90％，而对正常细胞则没有任何副作用，是最理想的抗癌药物。
将军炭：味苦，寒。归脾、胃、大肠、肝、心包经。泻热通肠，凉血解毒，逐瘀通经，化瘀止血。注意孕妇慎用。将军炭对恶性黑色素瘤有很强的抑制作用，恶性黑色素瘤对将军炭有特异性敏感。
金不换：味甘、微苦，温。归肝、胃经。散瘀止血，消肿定痛。注意孕妇慎用。金不换能增强被激活的免疫细胞的杀伤能力，能杀死恶性黑色素瘤。
天花粉：甘、微苦，微寒。归肺、胃经。清热生津，消肿排脓。天花粉对绒膜癌细胞有高度专一的亲和性和特殊的细胞毒性，显著抑制恶性黑色素瘤细胞的增殖，延长患者生存期。
芦笋：甘；寒。清热生津；利水通淋。脾胃虚寒者慎服。芦笋提取液能显著抑制恶性黑色素瘤的细胞增殖，影响其细胞周期,诱导其细胞凋亡和坏死。芦笋有防止癌细胞扩散的功能，对恶性黑色素瘤有特殊疗效。
啤酒花：苦；性微凉。归肝；胃经。健胃消食；利尿消肿；抗痨消炎。啤酒花能显著抑制内皮细胞增殖，具有显著抗肿瘤作用，是抑制各种肿瘤的血管形成疾病、恶性肿瘤生长和转移的有效药物。
本发明是由中国传统的中草药制成，根据中医辨证论治及现代医学的若干原则，以某些成分确定、功效明晰的天然提取物的有序配伍，组合成了有诱导恶性黑色素瘤细胞凋亡与促使其分化的中药。
本发明既有化学治疗之功，又平和无毒，可谓“零毒化疗”。 用药多年来，患者无任何不良反应，跟踪血液检查正常，且疗效不反弹。治愈率30%，5年生存率65%，有效率100%。
本发明可以使各中药成分在发挥其抗癌作用的同时相互协同，相辅相成，可以起到相互促进的作用，既能抑制恶性黑色素瘤细胞的增值，又能杀死恶性黑色素瘤细胞诱导恶性黑色素瘤细胞凋亡，起到治疗恶性黑色素瘤的作用。本发明与手术治疗相结合可以促进患者康复，预防术后肿瘤的复发和转移，快速帮助患者康复。
本发明能够帮助晚期恶性黑色素瘤患者改善症状、减轻痛苦、提高病人生存质量。对于已复发或转移及无法进行西医手术、放化疗治疗的患者，通过单独服用本配方中药，增强机体免疫功能，诱导恶性黑色素瘤细胞分化和凋亡，也可以达到延长病人生命的作用，甚至有可能带瘤生存。
本发明所述的中药组合物可用于治疗恶性黑色素瘤，具有显著疗效。本发明治疗费用相对低廉，远远低于西医的治疗费用。
本发明的中药组合物原料易得，工艺简单，成本低，效率高，有利于制药企业进行药品生产、质量控制；产品价格低，易于被患者接受。
本发明还提供了一种由上述治疗该病的中药组合物制成的口服制剂，所述口服制剂包括口服液、片剂、胶囊剂、丸剂等，优选剂型为口服液和胶囊剂，一日一剂，分早晚两次服用。
本发明的中药组合物可以制备成多种剂型。例如，将煎煮后的药液杀菌消毒后装袋，制成口服液；或者将煎煮后的药液进行浓缩，烘干后，加入医学上可接收的辅料，然后制成片剂、胶囊剂、丸剂等。
所述医学上可接收的辅料包括淀粉、糊精、羧甲基纤维素钠、聚乙二醇、磷酸氢钙、海藻酸钠、山梨酸钾等。
以上所述，仅是本发明的较佳实施例而已，并非对本发明作任何形式上的限制，本领域技术人员利用上述揭示的技术内容做出些许简单修改、等同变化或修饰，均落在本发明的保护范围内。
Claims (4)
1.一种治疗恶性黑色素瘤的中药，其特征是由下列重量份的原料药组成：吴茱萸2～4重量份；金不换、啤酒花4～8重量份；天花粉、龙牙草10～20重量份；黑大豆、飞扬草、将军炭15～30重量份；芦笋30～60重量份。
2.根据权利要求1所述的一种治疗恶性黑色素瘤的中药，其特征是由下列重量份的原料药组成：吴茱萸4重量份；金不换、啤酒花8重量份；天花粉、龙牙草20重量份；黑大豆、飞扬草、将军炭30重量份；芦笋60重量份。
3.一种治疗恶性黑色素瘤的口服制剂，其特征是由权利要求1或2中任一项所述的中药组合物制成。
4.根据权利要求3所述的一种治疗恶性黑色素瘤的口服制剂，其特征是，所述口服制剂包括口服液、片剂、胶囊剂、丸剂，优选口服液和片剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010821414.6A CN112426491A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗恶性黑色素瘤的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010821414.6A CN112426491A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗恶性黑色素瘤的中药组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112426491A true CN112426491A (zh) | 2021-03-02 |
Family
ID=74690526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010821414.6A Withdrawn CN112426491A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗恶性黑色素瘤的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112426491A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103656600A (zh) * | 2013-12-22 | 2014-03-26 | 青岛琴诚医药技术有限公司 | 一种十二温经丸的制备方法及应用 |
| CN104888128A (zh) * | 2015-06-22 | 2015-09-09 | 周崇立 | 一种治疗癌症的中药组合物 |
| CN107789466A (zh) * | 2016-08-30 | 2018-03-13 | 苏州瑞美科生物技术有限公司 | 一种用于治疗肿瘤的药物组合物 |
| CN108888741A (zh) * | 2018-09-30 | 2018-11-27 | 珠海市浩瀚兴华科技发展有限公司 | 一种抗肿瘤的中药组合物及其制备方法 |
-
2020
- 2020-08-15 CN CN202010821414.6A patent/CN112426491A/zh not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103656600A (zh) * | 2013-12-22 | 2014-03-26 | 青岛琴诚医药技术有限公司 | 一种十二温经丸的制备方法及应用 |
| CN104888128A (zh) * | 2015-06-22 | 2015-09-09 | 周崇立 | 一种治疗癌症的中药组合物 |
| CN107789466A (zh) * | 2016-08-30 | 2018-03-13 | 苏州瑞美科生物技术有限公司 | 一种用于治疗肿瘤的药物组合物 |
| CN108888741A (zh) * | 2018-09-30 | 2018-11-27 | 珠海市浩瀚兴华科技发展有限公司 | 一种抗肿瘤的中药组合物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 徐宏喜等: "《抗肿瘤中药现代研究与临床应用》", 28 February 2019, 上海科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108210657A (zh) | 一种预防和治疗肺癌的中药组合物 | |
| WO2020042665A1 (zh) | 一种鲨鱼软骨糖蛋白及其抗癌用途 | |
| CN113304226A (zh) | 一种治疗肺癌的中药组合物 | |
| WO2018171672A1 (zh) | 一种抗癌药物组合物及其用途 | |
| CN113368205A (zh) | 一种治疗胃癌的中药组合物 | |
| CN112426491A (zh) | 一种治疗恶性黑色素瘤的中药组合物 | |
| CN112426500A (zh) | 一种治疗宫颈癌的中药组合物 | |
| CN112316071A (zh) | 一种治疗肝癌的中药组合物 | |
| CN112426478A (zh) | 一种治疗肠癌的中药组合物 | |
| CN112426475A (zh) | 一种治疗淋巴细胞白血病的中药组合物 | |
| CN112426469A (zh) | 一种治疗艾氏腹水癌的中药组合物 | |
| CN112426486A (zh) | 一种治疗早幼粒细胞白血病的中药组合物 | |
| CN112245518A (zh) | 一种治疗粒细胞型白血病的中药组合物 | |
| CN112426465A (zh) | 一种治疗鼻咽癌、鳞状细胞癌的中药组合物 | |
| CN112426466A (zh) | 一种治疗各种癌症的中药组合物 | |
| CN115317567A (zh) | 一种增加肿瘤患者食欲的组合物及其制备方法 | |
| CN113648391A (zh) | 一种治疗白血病的中药组合物 | |
| CN114191480A (zh) | 一种中药组合物在制备防治慢性胃炎的药物中的应用 | |
| CN110638948A (zh) | 一种治疗消化不良的中药制剂 | |
| CN111714601A (zh) | 一种治疗真菌感染的中药组合物 | |
| CN106668227A (zh) | 回族中药参芪胃癌消口服液及其制备方法 | |
| CN107670012A (zh) | 一种内科抗肿瘤中药组合物 | |
| CN106668225A (zh) | 回族中药参芪胃癌消片及其制备方法 | |
| CN106668224A (zh) | 回族中药参芪胃癌消丸及其制备方法 | |
| CN106668730A (zh) | 回族中药红豆胃癌消丸及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210302 |
|
| WW01 | Invention patent application withdrawn after publication |